Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis

Bruce Y. Lee, Ann E. Wiringa, Rachel R. Bailey, G. Jonathan Lewis, Jared Feura, Robert R. Muder

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

Original languageEnglish (US)
Pages (from-to)2465-2471
Number of pages7
Issue number12
StatePublished - Mar 11 2010
Externally publishedYes


  • Computer simulation
  • Economics
  • Orthopedic surgery
  • Staphylococcus aureus
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis'. Together they form a unique fingerprint.

Cite this